Attached files

file filename
EX-99.1 - Cellectar Biosciences, Inc.v221570_ex99-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
___________________
 
FORM 8-K
___________________
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report:  May 9, 2011
(Date of earliest event reported)
 
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
333-119366
 
04-3321804
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)
 
One Gateway Center, Suite 504
Newton, MA  02458
(Address of principal executive offices)
 
(617) 244-1616
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written  communications  pursuant to Rule 425 under the  Securities  Act (17 CFR 230.425)
 
o
Soliciting  material  pursuant to Rule  14a-12  under the  Exchange  Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
 
 

 

ITEM 7.01          REGULATION FD DISCLOSURE  
 
On May 9, 2011, we issued a press release announcing that our trading symbol has reverted to NVLT following a twenty day post-split trading period.  A copy of the press is furnished as Exhibit 99.1 and is incorporated by reference in this Item.
 
 
ITEM 9.01          FINANCIAL STATEMENTS AND EXHIBITS

    c)     Exhibits

Number
 
Title
     
99.1
 
Press Release dated May 9, 2011 entitled “Novelos Therapeutics Trading Symbol Reverts to NVLT”
     


 
- 2 -

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


       
 Dated: May 9, 2011
NOVELOS THERAPEUTICS, INC.
 
     
     
 
By:  
/s/ Harry S. Palmin  
 
   
Harry S. Palmin
 
   
President and Chief Executive Officer
 
 
 

 
- 3 -

 
 
EXHIBIT INDEX


Number
 
Title
     
99.1
 
Press Release dated May 9, 2011 entitled “Novelos Therapeutics Trading Symbol Reverts to NVLT”
     

 
- 4 -